Genelux GNLX
NASDAQ GNLX
$2.00 +0.02 (+1.01%)
At close: Oct 23, 2026 · 4:00 PM EDT

Genelux (GNLX) Return on Capital Employed [ROCE] (2023 - 2026)

Updated

Genelux (GNLX) posted Return on Capital Employed [ROCE] of -187.59% for Q1 2026, up 22.86 percentage points from the prior quarter.

Analysis

Genelux (GNLX) Return on Capital Employed [ROCE] (2023 - 2026) Analysis & Trends

For FY2025, Genelux's Return on Capital Employed [ROCE] came in at -160.87%, down 30.98 percentage points from FY2024.

  • In prior years, Genelux's Return on Capital Employed [ROCE] was -129.89% in FY2024 (+108.00 pp) and -237.89% in FY2023.
  • Quarterly Return on Capital Employed [ROCE] has run from a low of -210.45% in Q4 2025 to a high of -77.88% in Q3 2024 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 17.52%
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 17.92%
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn 6.28%
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 19.32%
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 16.76%
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 16.66%
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn -5.97%
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 11.86%
10 Genelux 87.86 Mn 26.14 Mn - -187.59%
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 -187.59%
Dec 31, 2025 -210.45%
Sep 30, 2025 -142.82%
Dec 31, 2024 -103.62%
Sep 30, 2024 -77.88%
Jun 30, 2024 -93.79%
Mar 31, 2024 -139.71%
Dec 31, 2023 -98.92%
API Access

Genelux Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=GNLX&period=max&api_key=YOUR_API_KEY